|
|||||
|
|

Food ingredient solutions provider Ingredion (NYSE:INGR) fell short of the markets revenue expectations in Q4 CY2025, with sales falling 2.4% year on year to $1.76 billion. Its non-GAAP profit of $2.53 per share was 3.1% below analysts’ consensus estimates.
Is now the time to buy INGR? Find out in our full research report (it’s free for active Edge members).
Ingredion’s fourth quarter results drew a positive market response, despite revenue and non-GAAP profit falling short of Wall Street expectations. Management attributed the operational challenges largely to production issues at the Argo facility, which led to reduced inventory and lower sales in the Food and Industrial Ingredients U.S./Canada segment. CEO James Zallie highlighted ongoing strength in the Texture and Healthful Solutions segment, especially clean label and solutions-driven sales. Zallie explained, “Texture and Healthful Solutions posted its seventh straight quarter of volume growth, up 4%,” emphasizing the segment’s momentum even as broader industry sweetener demand remained soft.
Looking ahead, Ingredion’s guidance reflects an expectation of gradual recovery in its U.S./Canada operations and continued strength in higher-margin segments. Management believes that the ongoing recovery at the Argo plant and rising demand for clean label and protein fortification will be key drivers. CFO Jim Gray flagged persistent manufacturing cost inflation and mixed demand trends as headwinds, stating, “We anticipate continued challenges through the first quarter, in line with the previous quarter.” Management also referenced targeted investments in capacity and productivity, with Zallie noting that “the actions we are taking should lead to steadily improving performance throughout 2026.”
Ingredion’s Q4 performance was shaped by a mix of operational setbacks and segment outperformance, with particular strength in clean label solutions and protein fortification amid ongoing cost and volume pressures.
Ingredion’s outlook centers on recovering U.S./Canada operations, continued demand for clean label and protein solutions, and managing cost inflation across key segments.
Looking forward, the StockStory team will be watching (1) the pace of operational recovery and inventory normalization at the Argo facility, (2) the continued adoption and margin impact of clean label and protein fortification products, and (3) the ability of LatAm and Asia Pacific segments to sustain higher-margin growth despite external headwinds. Execution on enterprise productivity initiatives and effective capital allocation will also be important markers of progress.
Ingredion currently trades at $118.40, in line with $117.31 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.
The names generating the next wave of massive growth are right here in our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
| Feb-11 | |
| Feb-10 | |
| Feb-04 | |
| Feb-03 | |
| Feb-03 | |
| Feb-03 | |
| Feb-03 | |
| Feb-03 | |
| Feb-03 | |
| Feb-03 | |
| Feb-01 | |
| Jan-26 | |
| Jan-22 | |
| Jan-22 | |
| Jan-21 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite